万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>内分泌学与代谢

DIABETOLOGIA《糖尿病学》 (官网投稿)

简介
  • 期刊简称DIABETOLOGIA
  • 参考译名《糖尿病学》
  • 核心类别 高质量科技期刊(T2), SCIE(2024版), 目次收录(维普),外文期刊,
  • IF影响因子
  • 自引率2.60%
  • 主要研究方向医学-ENDOCRINOLOGY & METABOLISM内分泌学与代谢

主要研究方向:

等待设置主要研究方向
医学-ENDOCRINOLOGY & METABOLISM内分泌学与代谢

DIABETOLOGIA《糖尿病学》(月刊)。Diabetologia publishes original clinical and experimental research within the field of diabetes. We are interested in ...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、官网网址:https://diabetologia-journal.org/

3、投稿网址:http://mc.manuscriptcentral.com/diabetologia

4、期刊刊期:月刊,一个月出版一期。

2021430星期五

                            

 

投稿须知

【官网信息】

 

Instructions to Authors

Systematic Reviews

Authors should register their systematic review in a publicly accessible database e.g. PROSPERO. Please note that Diabetologia may, in the future, refuse to consider systematic reviews that have been registered after data extraction has begun.

Types of articles

Original articles

A maximum of 4000 words in the main text plus up to 50 references. The abstract, references, tables and figure legends are excluded from the word count, as are acknowledgements and other end matter. Please note that slightly overlength manuscripts will still be considered however authors will be asked to shorten their paper if the article survives peer review. Authors of manuscripts that are significantly overlength may be asked to reduce the number of words prior to their paper going for peer review. Please go to Organisation and content of papers below for information on structuring your article.

Short communications

A maximum of 1500 words in the main text plus approximately ten references and normally no more than two illustrations (tables or figures or one of each). Please go to Organisation and content of papers below for information on structuring your article.

Reviews

Reviews for Diabetologia are commissioned directly, and we no longer routinely consider unsolicited reviews for publication.

Systematic Reviews

A maximum of 4000 words in the main text with unlimited references. Authors must register their study in a publicly accessible database e.g. PROSPERO and include the registration number in the manuscript. Diabetologia may, in the future, refuse to consider systematic reviews that have been registered after data extraction has begun. The study protocol should be submitted as supplementary material.

There is no need to contact the Editor-in-Chief before submitting a systematic review; please upload at https://mc.manuscriptcentral.com/diabetologia in the usual way, along with a PRISMA or MOOSE checklist. See Reporting guidelines.

Meta-analyses

A maximum of 4000 words in the main text with unlimited references. We recommend that authors register their study in a publicly accessible database and submit the study protocol as supplementary material.

There is no need to contact the Editor-in-Chief before submitting a meta-analysis; please upload at https://mc.manuscriptcentral.com/diabetologia in the usual way.

For meta-analyses of randomised controlled trials, follow PRISMA reporting guidelines – include a flow diagram in your manuscript and submit a completed PRISMA checklist.

For meta-analyses of observational studies in epidemiology, follow MOOSE reporting guidelines and submit a completed MOOSE checklist.

For Debate

A maximum of 2500 words in the main text plus up to 40 references and two illustrations (tables or figures or one of each). These will normally be solicited by the Editor-in-Chief although unsolicited articles will be considered.

Letters to the Editor

A maximum of 1000 words, plus 8 references and normally no more than one table or one figure. Letters are the forum for either: (1) Correspondence – comments with critical assessment of papers recently published in Diabetologia which, at the Editor-in-Chief’s discretion, will be sent to the authors of the original paper for comment and both letter and reply published together; or (2) Research letters – observations providing concise and important new information. Research letters are formatted as letters, i.e. in individual paragraphs with no headings and no abstract.

The lead authors of Letter-responses are responsible for contacting all authors of the original paper to ascertain whether they wish to be included in the reply.

Authors whose papers exceed permitted word counts at the point of submission will be asked to shorten their paper if the article survives peer review.

Organisation and content of papers

Diabetologia does not insist that authors follow journal guidelines in terms of length of article or formatting at the point of submission but authors of overlength articles will be asked to reduce the word count if their article survives peer-review and accepted articles will be brought into line with journal style by copyeditors.

Reporting checklist

Diabetologia insists on submission of a completed checklist alongside a manuscript in an attempt to ensure that the study is reported accurately and thoroughly. See Reporting guidelines.

Title page

This page should state:

Title of paper (including animal species if appropriate);

Authors’ names (given name, initials and family name – no qualifications) – please add a note if there are co-first authors;

Institution(s) of origin;

ORCID identifiers where possible;

Corresponding author and email address (co-corresponding authors are permitted, please ensure this is clear);

Word count (excluding abstract, research in context, references, acknowledgements, funding statement, authors’ relationships and activities, contribution statement, tables and figure legends).

Abstract

Abstracts should be structured into four paragraphs as follows: (1) Aims/hypothesis; (2) Methods; (3) Results; (4) Conclusions/interpretation. The Abstract should contain data to support the main results of your paper. Please do not include unexplained abbreviations. There is no upper word limit.

Please include numerical data in your abstract to support the main findings of your paper, if appropriate. (Our word limit for abstracts is flexible.) Please make sure the data in your abstract can also be found easily in the Results section of your paper or in the tables, and make sure that data are reported consistently in the Abstract and Results, and to the same number of decimal places.

For clinical trials, the trial registry number should be included at the end of the Abstract.

For randomised controlled trials (RCTs), abstracts should include the checklist items set out in the CONSORT guidelines.

If data have been deposited in a public repository authors should include the dataset name and repository name and number at the end of the Abstract.

Graphical abstracts

Authors whose papers (reviews, original articles and short communications) survive the initial round of peer-review will be asked to supply a graphical abstract with their revised version. Please note that this does not need to be supplied at first submission.

The aim of a graphical abstract is to give readers a visual summary of the main message of the paper. Graphical abstracts will appear in the html version of a paper (not the pdf) and will also be used in Diabetologia’s electronic tables of contents (eTOC) alerts, on our website and on twitter. For examples, please click here.

In line with Cell Press’s guidelines for graphical abstracts, please ensure that your graphical abstract meets the following criteria:

Content

The graphical abstract should:

Have a clear start and end, ‘reading’ from toptobottom or lefttoright

Provide a visual indication of the biological context of the results depicted (subcellular location, tissue or cell type, species, etc)

Emphasise the new findings from the current paper without including excess details from previous literature

Avoid the inclusion of speculative features (unless the speculative nature can be made apparent visually)

Limit use of data items (maximum one graph)

Not include abbreviations unless these are defined within the graphical abstract

Not be a repetition of one of the figures already included in the paper, although authors may wish to develop one of the figures, simplify a schematic or incorporate elements of several figures

The graphical abstract should also:

Use simple labels

Use text sparingly

Highlight one process or make one point clear

Be free of distracting and cluttering elements

 Permission/acknowledgement

Please note that it is the authors’ responsibility to check whether permission or an acknowledgement is required for any part of the graphical abstract and to include details of any acknowledgements on the title page of the manuscript. We can then insert the appropriate wording on the graphical abstract for you. Images from illustration providers (e.g. Servier Medical Art, Wikimedia Commons or Biorender) may need to be accompanied by an acknowledgement of the source and/or may require payment for the right to use the image or a licence to publish. It is important to check the original source of images found on other websites as licences may be required—this can often be checked via google images. Figures/tables taken or adapted from other published sources may require permission from the publisher and/or author.

The following sources have images that are free to reuse, and there are numerous other similar websites where you may find suitable images; however, it is important to check licensing terms for each image, as these may differ between images from the same source:

pixabay

Wikimedia Commons

unsplash

the Noun Project

stockvault

Format

TIFF (at least 300 dpi), Powerpoint, EPS, PDF

Sans serif font e.g. Helvetica or Arial. Please use the same font for all figure labels

Font size: 12–16 points

The graphical abstract should be one single panel

Avoid heavily saturated, primary colours. You may wish to consult the Diabetologia colour palette (https://diabetologia-journal.org/wp-content/uploads/2018/08/Full-colour-palette-for-schematics-and-diagrams.ai.pdf)

Tweet

We are committed to making your research as widely accessible as possible and will tweet (@DiabetologiaJnl) about accepted articles (reviews, original articles and short communications). Please include a tweet along with institutional and personal twitter handles and relevant hashtags (maximum of 250 characters, including spaces) on the title page of your article. Your tweet can be based on the title of your paper or the main finding(s). We will include your graphical abstract with the tweet.

Keywords

Up to ten keywords should be provided, in alphabetical order, at the end of the Abstract.

Abbreviations

Please use abbreviations only when necessary and define them in a separate list, in alphabetical order, given after the keywords. Abbreviations should not normally appear in the title or Abstract. Do not abbreviate type 1 diabetes / type 2 diabetes (only permissible in tables and figures when the abbreviation should be explained in the legend or footnote). Endocrine pancreatic cells should be designated as beta cells (not ß cells or b cells), alpha cells, delta cells and pancreatic polypeptide cells. Please note we have a list of accepted abbreviations that do not need to be defined in the text or included in the abbreviations list.

Research in context

For submissions of original articles, short communications, systematic reviews and meta analyses, please insert a ‘Research in context’ summary (<200 words) below the abstract to include the following questions and your responses:

What is already known about this subject? (maximum of 3 bullet points)

What is the key question? (one bullet point only; formatted as a question)

What are the new findings? (maximum of 3 bullet points)

How might this impact on clinical practice in the foreseeable future? (one bullet point only)

Introduction

The Introduction should contain a clear statement of the aim and novelty of the study. It should include neither results nor conclusions.

Methods

Sufficient information should be given to allow a knowledgeable reader to understand what was done, and how, and to assess the biological relevance of the study and the reliability and validity of the findings.

The methods must be detailed enough that others with access to the data would be able to reproduce the results. If results in a paper published in Diabetologia cannot be reproduced the journal will consider publication of refutations of that paper.

If an organisation was paid or otherwise contracted to help conduct the research (e.g. data collection and management) then this should be detailed in the methods.

Clinical trials mentioned in the text The International Committee of Medical Journal Editors (ICMJE) recommends that, where trials are mentioned, for example in secondary analyses or meta-analyses, the trial registration number should be included at first mention of the trial in the manuscript.

Description of patients/participants Detailed descriptions should be provided of the individuals’ clinical characteristics (including the type of diabetes e.g. type 1 diabetes, type 2 diabetes, GDM) upon which individuals were classified. Note: diabetic should not be used as a noun, e.g., ‘diabetics’. Relative body weight should be expressed in terms of body mass index, i.e. (weight in kg)/(height in metres)2 (not % ideal body weight).

Informed consent and ethics committee approval A paper describing experimental work in humans must (1) indicate that informed consent has been obtained from patients where appropriate, (2) include a statement that the responsible ethics committee (institutional review board) has given approval, and/or indicate that the reported investigations have been carried out in accordance with the principles of the Declaration of Helsinki as revised in 2008. For studies in children/minors, where informed consent has been provided by the parent or guardian, assent should also be given directly by the child, where practical. Please mention in your paper whether this has been sought and obtained. Do not use participant names, initials or hospital numbers, especially in illustrative material. For studies involving human embryos, gametes and stem cells, please see Springer’s policy guidelines and ensure that the manuscript includes an ethics statement identifying the institutional and/or national research ethics committee approving the experiments and describing any relevant details. Authors should confirm that informed consent was obtained from all recipients and/or donors of cells or tissues, where necessary, and describe the conditions of donation of materials for research, such as human embryos or gametes. Uniform requirements should be followed for ethical standards.

Matching Please give matching criteria for continuous variables, e.g. age +/- 2 years, BMI +/- 1 kg/m2. If these variables were not actually matched and were simply similar between the three groups, then please make this clear.

……


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭